Antibodies

26 Jul 2021 HBM Presents Phase I Data on Next-Generation Anti-CTLA-4 Antibody at ESMO Congress 2021
26 Jul 2021 Denali Therapeutics Announces Positive Interim Data from Phase 1/2 Study with ETV:IDS (DNL310) in Patients with the Lysosomal Storage Disease Hunter Syndrome (MPS II)
26 Jul 2021 Ultomiris recommended for approval in the EU by CHMP for children and adolescents with paroxysmal nocturnal haemoglobinuria
24 Jul 2021 Incyte Provides Regulatory Update on Retifanlimab for the Treatment of Certain Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)
23 Jul 2021 Lee’s Pharmaceutical Announces First Patient Dosed With its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, as a First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer
23 Jul 2021 Annexon Broadens Autoimmune Franchise with Advancement of Third Anti-C1q Product Candidate and Strategic Expansion into New Autoantibody-driven Diseases
23 Jul 2021 Inhalon Collaborates with Celltrion, Inc. to Develop Nebulized Form of Regdanvimab to Treat COVID-19 Patients at Home
23 Jul 2021 ImmunoPrecise's PolyTope™ TATX-03 Antibody Cocktail Potently Neutralizes SARS-CoV-2 Delta Variant in in vitro Pseudovirus Assays
23 Jul 2021 Adagene Announces Clinical Trial Collaboration With Merck to Advance Two Anti-CTLA-4 Monoclonal Antibody Programs (ADG116 and ADG126) in Combination Therapy with KEYTRUDA® (pembrolizumab)
22 Jul 2021 FDA Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma
22 Jul 2021 Sorrento Announces Dosing of COVID-19 Patients in Phase 2 Clinical Trial for COVIDROPS, a Highly Potent Neutralizing Antibody Against SARS-CoV-2 Including Delta and Alpha Variants of Concern, in an At-Home Outpatient Setting in United Kingdom
22 Jul 2021 Sorrento Announces That Its Subsidiary Levena and Its Partner Escugen Have Received Clearance to Begin Clinical Trials With Anti-TROP-2 Antibody Drug Conjugate For Multiple Solid Tumors
22 Jul 2021 Hemab Raises US$ 55M Series A to Advance Next Generation Therapeutics for Bleeding and Thrombosis Disorders
22 Jul 2021 Intas Enters into an Exclusive License Agreement with Meiji and Dong-A ST to commercialize DMB-3115 (Proposed Biosimilar to Ustekinumab)
22 Jul 2021 Magenta Therapeutics Announces Update on U.S. FDA Investigational New Drug Application for MGTA-117 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome
20 Jul 2021 Prometheus Biosciences Announces Initiation of Global Phase 2 Clinical Trial of PRA023 in Moderate-to-Severe Ulcerative Colitis (UC)
20 Jul 2021 Anthos Therapeutics' novel Factor XI inhibitor abelacimab significantly outperforms standard of care enoxaparin in prospective Phase 2 efficacy research published today in the New England Journal of Medicine
20 Jul 2021 Aronora Reports Positive Topline Data From Phase 2 Study of AB023 in Hemodialysis Patients
20 Jul 2021 Aridis Pharmaceuticals Announces Exclusive License of Suvratoxumab, a Phase 3-Ready Monoclonal Antibody, from AstraZeneca
20 Jul 2021 Immunome Antibody Cocktail (IMM-BCP-01) Neutralizes the SARS-CoV-2 Delta Variant in Pre-clinical Testing
19 Jul 2021 Samsung Bioepis Initiates Phase 3 Clinical Trial for SB17, Proposed Biosimilar to Stelara (Ustekinumab)
16 Jul 2021 Bristol Myers Squibb Provides Update on CheckMate -651 Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Versus EXTREME Regimen as First-Line Treatment for Squamous Cell Carcinoma of the Head and Neck
16 Jul 2021 Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI319 (Anti-PD-1/CD137 Bispecific Antibody) in Patients with Advanced Malignant Tumors
16 Jul 2021 Celltrion’s Monoclonal Antibody Treatment for COVID-19, regdanvimab (CT-P59), Demonstrates Strong Neutralising Activity Against Delta Variant
16 Jul 2021 Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized Myasthenia Gravis (gMG)

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2020 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top